DV
Dividend Vision

MANE — Veradermics, Incorporated

Veradermics, Incorporated (MANE)

Total return is 198.6% over the past 0.5 years, 184.9 points ahead of SPY at 13.7%.

Veradermics, Incorporated is a clinical-stage biopharmaceutical company developing novel therapeutics for dermatologic and aesthetic conditions, including oral and topical treatments for pattern hair loss, alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. As an early-stage biotech company with no approved products on the market, it does not currently generate revenue from product sales and does not distribute dividends. This security appeals to investors with high risk tolerance seeking exposure to dermatology-focused drug development.

MANE key facts

Asset type
Stock
Asset class
Equity
Inception date
02/04/2026
Distribution frequency
None
Last close
$112.71
Market cap
$4,709,039,104
Average volume
523400.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.50